Cotinga Pharmaceuticals Debt/Equity
What is the Debt/Equity of Cotinga Pharmaceuticals?
The Debt/Equity of Cotinga Pharmaceuticals, Inc. is -1.52
What is the definition of Debt/Equity?
Debt to equity ratio is a financial ratio indicating the relative proportion of shareholders’ equity and debt used to finance a company’s assets.
lfy (last fiscal year)
The debt to equity ratio is generally calculated by dividing debt by equity. The D/E ratio is also known as risk, gearing or leverage. The two components are often taken from the firm's balance sheet or statement of financial position (so-called book value), but the ratio may also be calculated using market values for both, if the company's debt and equity are publicly traded, or using a combination of book value for debt and market value for equity financially. Preferred stock can be considered part of debt or equity. Attributing preferred shares to one or the other is partially a subjective decision but will also take into account the specific features of the preferred shares. When used to calculate a company's financial leverage, the debt usually includes only the long-term debt.
Debt/Equity of companies in the Health Care sector on TSXV compared to Cotinga Pharmaceuticals
What does Cotinga Pharmaceuticals do?
Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.
Companies with debt/equity similar to Cotinga Pharmaceuticals
- The State Trading of India has Debt/Equity of -1.54
- Aquestive Therapeutics Inc has Debt/Equity of -1.54
- Routemaster Capital has Debt/Equity of -1.54
- NeutriSci International has Debt/Equity of -1.54
- Citrine Global, Corp has Debt/Equity of -1.53
- DomaCom has Debt/Equity of -1.53
- Cotinga Pharmaceuticals has Debt/Equity of -1.52
- Alpha Cognition has Debt/Equity of -1.52
- Sequana Medical NV has Debt/Equity of -1.52
- Greenbrook TMS has Debt/Equity of -1.51
- Resources of Australia Ltd has Debt/Equity of -1.51
- Mobio Technologies has Debt/Equity of -1.51
- PowerBand Solutions has Debt/Equity of -1.51